Curis (CRIS) Tops Q4 EPS by 3c, Revenues Beat

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Curis (CRIS) Tops Q4 EPS by 3c, Revenues Beat

Pre-Open Stock Movers 03/25: (CRIS) (AVYA) (AIMT) Higher; (PTI) (REPH) (AKAM) Lower (more...)

March 25, 2019 9:26 AM EDT

Today's Pre-Open Movers

Curis, Inc. (NASDAQ: CRIS) 81% HIGHER; entered into an agreement with funds managed by Oberland Capital Management, LLC for up to $135.7 million in exchange for selling rights to a portion of royalty revenues on worldwide net sales of Erivedge.

Proteostasis Therapeutics, Inc. (NASDAQ: PTI) 53.3% LOWER; announced results from Phase 1 clinical studies of its proprietary cystic fibrosis transmembrane conductance regulator (CFTR)... More

Curis (CRIS) Sells Portion of Erivedge Royalties for up to $135.7 million

March 25, 2019 8:31 AM EDT

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that it has entered into an agreement with funds managed by Oberland Capital Management, LLC ("Oberland Capital") for up to $135.7 million in exchange for selling rights to a portion of royalty revenues on worldwide net sales of Erivedge.

Under the terms of the agreement, Curis... More